Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 4,803 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sensitivity Clear all
Withdrawn No phase listed Observational

Diesel Exhaust Particles and Leukotriene Production

NCT00915447
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 23, 2026, 3:53 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Glucose and Lipid Metabolism in Adolescents

NCT00998855
View directory record Official record
Conditions
Exercise, Obesity, Insulin Sensitivity
Interventions
Exercise
Behavioral
Lead sponsor
National Institutes of Health (NIH)
NIH
Eligibility
13 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Oct 23, 2026, 3:53 PM EDT
Completed No phase listed Observational

Replication of the P04334 Asthma Trial in Healthcare Claims Data

NCT04892758
View directory record Official record
Conditions
Asthma
Interventions
Formoterol fumarate 10 mcg, Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
12 Years to 120 Years
Enrollment
10,288 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Phase 3 Interventional Results available

Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis

NCT01751126
View directory record Official record
Conditions
Vernal Keratoconjunctivitis
Interventions
NOVA22007 ''Ciclosporin'', Placebo
Drug
Lead sponsor
Santen SAS
Industry
Eligibility
4 Years to 18 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Glendale, California • Irvine, California • Rancho Cordova, California + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 23, 2026, 3:53 PM EDT
Active, not recruiting Phase 2 Interventional

Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)

NCT05254314
View directory record Official record
Conditions
Asthma
Interventions
Semaglutide Pen Injector 2.4mg weekly, Placebo
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 3:53 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis

NCT05155085
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
AK002, Placebo
Drug · Other
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
40
States / cities
Birmingham, Alabama • Cullman, Alabama • Gilbert, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 23, 2026, 3:53 PM EDT
Terminated Phase 4 Interventional Results available

The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.

NCT05696392
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ruxolitinib cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
30
States / cities
Fountain Valley, California • Long Beach, California • Washington D.C., District of Columbia + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 23, 2026, 3:53 PM EDT
Terminated Phase 2 Interventional

Hydrocortisone Ophthalmic Ointment 0.5% for Treatment of Allergic Conjunctivitis

NCT01860664
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
hydrocortisone ophthalmic ointment 0.5%, placebo
Drug
Lead sponsor
Koffler Vision Group
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 23, 2026, 3:53 PM EDT
Recruiting Phase 2 Interventional

Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity

NCT05933499
View directory record Official record
Conditions
Obesity
Interventions
Bimagrumab, Tirzepatide, Calcium/Vitamin D, Lifestyle and nutrition counseling
Drug · Dietary Supplement · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 23, 2026, 3:53 PM EDT
Recruiting Not applicable Interventional

Smart Inhaler and Remote Asthma Management in Adolescents With Intellectual and Developmental Disabilities

NCT07746921
View directory record Official record
Conditions
Asthma in Children, Intellectual Disabilities (F70-F79), Developmental Disability, Autism Spectrum Disorder
Interventions
Use of active remote smart inhaler in the home setting, Use of passive remote smart inhaler in the home setting
Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
10 Years to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Phase 3 Interventional

Perennial Allergic Rhinitis Study In Pediatric Subjects

NCT00108914
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
GW685698X
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Years to 12 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
43
States / cities
Costa Mesa, California • Cudahy, California • Long Beach, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Results available

This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines

NCT03926611
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 Arm 1, LOU064 Arm 2, LOU064 Arm 3, LOU064 Arm 4, LOU064 Arm 5, LOU064 Arm 6, Placebo arm
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
11
States / cities
Litchfield Park, Arizona • Little Rock, Arkansas • Mission Viejo, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Results available

Topical NanoDox® for Atopic Dermatitis

NCT02910011
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Nanodox 1% (doxycycline monohydrate hydrogel)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

NCT01172821
View directory record Official record
Conditions
Asthma
Interventions
placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Los Angeles, California • Stockton, California • Centennial, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Phase 3 Interventional

Study to Find Out Whether Participants With a History of Stuffy Nose Due to Allergic Reactions in the Nose Would Intend to Buy Drug Phenylephrine Hydrochloride Extended Release Tablets After Receiving it Once in This Study

NCT04534452
View directory record Official record
Conditions
Nasal Congestion Due to Allergic Rhinitis
Interventions
Phenylephrine HCl (Sinus Comfort, BAY112476)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Blue Bell, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Not applicable Interventional Results available

Olopatadine Eye Drops and Allergy Skin Testing

NCT00775658
View directory record Official record
Conditions
Allergic Rhinitis, Allergic Conjunctivitis
Interventions
olopatadine, placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Using Computers to Assist in the Treatment of Asthma in a Pediatric Setting

NCT01312805
View directory record Official record
Conditions
Asthma
Interventions
CHICA Asthma Module, CHICA Control
Other
Lead sponsor
Indiana University
Other
Eligibility
3 Years to 11 Years
Enrollment
2,098 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 23, 2026, 3:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Washington University Severe Asthma Research Program III

NCT01716494
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 23, 2026, 3:53 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition

NCT01428245
View directory record Official record
Conditions
Hyperandrogenemia, Polycystic Ovary Syndrome
Interventions
Progesterone, Estrace (estrogen)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
8 Years to 14 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Results available

Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies

NCT01206777
View directory record Official record
Conditions
Indolent or Intermediate Grade B-cell Malignancy
Interventions
Rituximab
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 89 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT01279057
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals), Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray, Placebo
Drug
Lead sponsor
Sandoz
Industry
Eligibility
12 Years and older
Enrollment
727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Results available

Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis

NCT01941537
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ILV-094, Placebo Comparator
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Phase 4 Interventional Results available

A Research Study Examining Migranal and Skin Sensitivity in Subjects With Migraine

NCT00335777
View directory record Official record
Conditions
Migraine
Interventions
Migranal nasal spray at 1 hour, Migranal nasal spray at 4 hour
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 23, 2026, 3:53 PM EDT
Completed Not applicable Interventional

Usage, Usability & Effect on Adherence and Clinical Outcomes of Text Message Reminders for Adolescents With Asthma

NCT01253330
View directory record Official record
Conditions
Asthma
Interventions
Text Message Reminders
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 22 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 23, 2026, 3:53 PM EDT